Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso
Intrauterine Growth Retardation is the most important determinant of mortality and morbidity in the neonatal period. It is also a very important factor in predicting nutritional status, health and development in childhood. It even influences health in adult life, contributing to the vicious cycle of disease and poverty. The high rate IUGR in DCs represents therefore a major public health problem. Maternal malnutrition is usually assumed to be a major determinant of the problem in these countries. An increasing amount of evidence points to the potential role played by micronutrient deficiencies during pregnancy. The adverse effect on birthweight of maternal iron deficiency anaemia, lack of zinc and lack of iodine have been documented. A similar effect is suspected for Vitamin A, Magnesium, Calcium, Copper,Thiamine, Pyridoxine and Folic acid. It seems that not one specific deficiency alone is responsible for this adverse effect, but rather a combination of them. Therefore, it is expected that covering needs of pregnant women by a multivitamin-mineral supplement will have an effect of public health importance on children's health.
This study has the objective of improving children's health by preventing intrauterine growth retardation through the provision of multivitamin-mineral supplements during pregnancy.
This research includes 2 constituents:
- a pilot phase during which socio-anthropological, nutritional and epidemiological aspects of IUGR will be assessed through qualitative and epidemiological methods.
- a double-blind, randomised, placebo-controlled trial, including 1215 pregnant women aimed at testing 3 hypotheses: supplementing pregnant women with a multivitamin-minerals mix will improve fetal growth; improved fetal growth will have a positive effect on health and growth during infancy; covering nutritional needs of lactating women with a multivitamin-minerals mix during 3 months after delivery will improve health and growth of infants.
The trial is planned in Hounde District, Burkina Faso, in collaboration with Centre Muraz, which plays a leader role in research and services providing at the district level and in policy recommendations at the national level. This will ensure that the study findings are incorporated into on-going district programmes with possible replication at the national level. The research lasts from June 2003 to October 2006.
|Multiple Micronutrient Deficiencies During Pregnancy||Dietary Supplement: Multiple micronutrient supplements (MMN) Dietary Supplement: IFA||Phase 4|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
|Official Title:||Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso|
- Weight, length and Rohrer index at birth, and gestational duration in single pregnancies. [ Time Frame: At birth ]
- Mortality, morbidity and growth during the first year of life [ Time Frame: Monthly during infancy ]
- LBW; SGA; thoracic circumference; head circumference; mid-upper arm circumference; hemoglobin concentration in mothers and in newborns; soluble sTfR in cord blood as an iron status indicator; preterm birth; stillbirth; perinatal death [ Time Frame: Different depending on mother and child ]
|Study Start Date:||June 2003|
|Study Completion Date:||October 2006|
|Primary Completion Date:||October 2006 (Final data collection date for primary outcome measure)|
multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg
Dietary Supplement: Multiple micronutrient supplements (MMN)
Iron and folic acid: iron 60 mg and folic acid 400µg
Active Comparator: IFA
iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
Dietary Supplement: IFA
Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
Show Detailed Description
Please refer to this study by its ClinicalTrials.gov identifier: NCT00642408
|Centre Muraz, 2054, Avenue Mamadou KONATE|
|Bobo-Dioulasso, Burkina Faso, BP 390|
|Principal Investigator:||Dominique Roberfroid, MD||ITM Antwerp|
|Principal Investigator:||Nicolas Meda, MD||Head of the Epidemiology Unit in Centre Muraz|
|Study Chair:||Patrick Kolsteren, MD||head of the Nutrition and Child Health Unit in the Institute of Tropical Medicine (ITM, Antwerp, Belgium)|